Cargando…
Efficacy of Rituximab in a Patient With Partial Clinical Remission and Persistent Circulating PLA2R-Ab
Autores principales: | Georges, Elodie, Johanet, Catherine, Plaisier, Emmanuelle, Debiec, Hanna, Ronco, Pierre, Dahan, Karine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609820/ https://www.ncbi.nlm.nih.gov/pubmed/31312775 http://dx.doi.org/10.1016/j.ekir.2019.03.002 |
Ejemplares similares
-
The Role of PLA2R Antibody in Treatment of Membranous Nephropathy
por: Dahan, Karine, et al.
Publicado: (2017) -
Efficacy and Safety of Rituximab in Hepatitis B Virus–Associated PLA2R-Positive Membranous Nephropathy
por: Berchtold, Lena, et al.
Publicado: (2017) -
Rituximab-Induced Remission in Epstein−Barr Virus−Associated Glomerulonephritis
por: Alabdaljabar, Mohamad S., et al.
Publicado: (2020) -
Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2021) -
Rituximab for Anti–Glomerular Basement Membrane Disease
por: Jain, Rashmi, et al.
Publicado: (2018)